Literature DB >> 17062422

The impact of acute care medications on rehabilitation outcome after traumatic brain injury.

W Jerry Mysiw1, Jennifer A Bogner, John D Corrigan, Lisa P Fugate, Daniel M Clinchot, Vivek Kadyan.   

Abstract

OBJECTIVES: To examine the impact of medications with known central nervous system (CNS) mechanisms of action, given during the acute care stages after traumatic brain injury (TBI), on the extent of cognitive and motor recovery during inpatient rehabilitation.
DESIGN: Retrospective extraction of data utilizing an inception cohort of moderate and severe TBI survivors.
METHODS: The records of 182 consecutive moderate and severe TBI survivors admitted to a single, large, Midwestern level I trauma centre and subsequently transferred for acute inpatient rehabilitation were abstracted for the presence of 11 categories of medication, three measures of injury severity (worst 24 hour Glasgow Coma Scale, worst pupillary response, intra-cranial hypertension), three measures of outcome (Function Independence Measure (FIM) Motor and Cognitive scores at both rehabilitation admission and discharge and duration of post-traumatic amnesia (PTA)). MAIN OUTCOME AND
RESULTS: The narcotics, benzodiazepines and neuroleptics were the most common categories of CNS active medications (92%, 67% and 43%, respectively). The three categories of medications appeared to have no significant outcome on the FIM outcome variables. The neuroleptics affected cognitive recovery with almost 7 more days required to clear PTA in the neuroleptic treated group. The presence of benzodiazepines did tend to obscure the impact of neuroleptics on PTA duration but the negative impact of neuroleptics on PTA duration remained significant.
CONCLUSIONS: The results suggest that the use of neuroleptics during the acute care stage of recovery has a negative impact on recovery of cognitive function at discharge from inpatient rehabilitation. Due to the paucity of subjects with hemiplegia in this cohort, conclusions could not be drawn as to the impact of acute care medications on motor recovery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17062422     DOI: 10.1080/02699050600743972

Source DB:  PubMed          Journal:  Brain Inj        ISSN: 0269-9052            Impact factor:   2.311


  7 in total

1.  Psychotropic Medication Use During Inpatient Rehabilitation for Traumatic Brain Injury.

Authors:  Flora M Hammond; Ryan S Barrett; Timothy Shea; Ronald T Seel; Thomas W McAlister; Darryl Kaelin; David K Ryser; John D Corrigan; Nora Cullen; Susan D Horn
Journal:  Arch Phys Med Rehabil       Date:  2015-08       Impact factor: 3.966

2.  Relative to Typical Antipsychotic Drugs, Aripiprazole Is a Safer Alternative for Alleviating Behavioral Disturbances After Experimental Brain Trauma.

Authors:  Thomas I Phelps; Corina O Bondi; Vincent V Mattiola; Anthony E Kline
Journal:  Neurorehabil Neural Repair       Date:  2016-05-24       Impact factor: 3.919

3.  Pharmacological interventions for agitation in patients with traumatic brain injury: protocol for a systematic review and meta-analysis.

Authors:  David R Williamson; Anne Julie Frenette; Lisa Burry; Marc M Perreault; Emmanuel Charbonney; François Lamontagne; Marie-Julie Potvin; Jean-François Giguère; Sangeeta Mehta; Francis Bernard
Journal:  Syst Rev       Date:  2016-11-17

4.  Pharmacological interventions for agitated behaviours in patients with traumatic brain injury: a systematic review.

Authors:  David Williamson; Anne Julie Frenette; Lisa D Burry; Marc Perreault; Emmanuel Charbonney; Francois Lamontagne; Marie-Julie Potvin; Jean-Francois Giguère; Sangeeta Mehta; Francis Bernard
Journal:  BMJ Open       Date:  2019-07-09       Impact factor: 2.692

5.  Prevalence and characteristics of neuropsychiatric symptoms, quality of life and psychotropics in people with acquired brain injury in long-term care.

Authors:  Roy Kohnen; Jan Lavrijsen; Odile Smals; Debby Gerritsen; Raymond Koopmans
Journal:  J Adv Nurs       Date:  2019-08-05       Impact factor: 3.187

6.  Use of olanzapine to treat agitation in traumatic brain injury: study protocol for a randomised controlled trial.

Authors:  Ruby K Phyland; Adam McKay; John Olver; Mark Walterfang; Malcolm Hopwood; Amelia J Hicks; Duncan Mortimer; Jennie L Ponsford
Journal:  Trials       Date:  2020-07-20       Impact factor: 2.279

Review 7.  Challenges of Delirium Management in Patients with Traumatic Brain Injury: From Pathophysiology to Clinical Practice.

Authors:  Shawniqua Williams Roberson; Mayur B Patel; Wojciech Dabrowski; E Wesley Ely; Cezary Pakulski; Katarzyna Kotfis
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.